Efficacy of sofosbuvir and ribavirin therapy in patients with genotype 2 hepatitis C virus: Significance of variants associated with resistance in NS3, NS5A and NS5B region

Efficacy of sofosbuvir and ribavirin therapy in patients with genotype 2 hepatitis C virus: Significance of variants associated with resistance in NS3, NS5A and NS5B region - Assessment of NS3, NS5A and NS5B amino acid mutations in genoytpe 2 HCV

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000018089

Enrollment

100

Registered

2015-06-26

Start date

2015-07-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the patients infected with genotype 2 HCV who received combination therapy with sofosbvir and rivabirin.

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: the patients infected with HCV genotype 2

Exclusion criteria

Exclusion criteria: the patients infected with HCV other than genotype 2

Design outcomes

Primary

Measure	Time frame
the efficacy of antiviral therapy at end of treatment and 4 week after.	—

Countries

Japan

Contacts

Public ContactYoshihito Uchida

Saitama Medical University Department of Gastroenterology & Hepatology

y_uchida@saitama-med.ac.jp049-276-1198

Outcome results